对于社保基金，本期较上一季度持股减少的社保基金共计1个，即全国社保基金一零一组合，，持股减 少占比小幅下跌。本期较上一季未再披露的社保基金共计1个，即全国社保基金四零一组合。 养老金视角，本期较上一季度持股减少的养老金基金共计1个，即基本养老保险基金八零八组合，持股 减少占比小幅下跌。 公募基金方面，本期较上一期持股增加的公募基金共计3个，包括南方中证500ETF、华泰紫金创新先锋 混合(LOF)C、海富通策略收益债券A，持股增加占比小幅上涨。本期较上一季度新披露的公募基金共计 8个，主要包括泰康医疗健康股票发起A、广发中证智选高股息策略ETF、南方中小盘成长股票A、信澳 价值精选混合A、天弘优质成长企业精选混合发起式A等。本期较上一季未再披露的公募基金共计5个， 包括南方品质优选灵活配置混合A、南方优享分红灵活配置混合A、南方产业活力股票、太平改革红利 精选、淳厚益加债券A。 2025年8月23日，济川药业(600566.SH)发布2025年半年度报告。截至2025年8月22日，共有18个机构投 资者披露持有济川药业A股股份，合计持股量达5.63亿股，占济川药业总股本的61.11%。其中，前十大 机构投资者 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 公司代码：600566 公司简称：济川药业 第一节 重要提示 1.1本半年度报告摘要来自半年度报告全文，为全面了解本公司的经营成果、财务状况及未来发展规 划，投资者应当到www.sse.com.cn网站仔细阅读半年度报告全文。 1.2本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确性、完整 性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 1.5董事会决议通过的本报告期利润分配预案或公积金转增股本预案 无 第二节 公司基本情况 2.1公司简介 ■ 2.2主要财务数据 单位：元 币种：人民币 ■ 2.3前10名股东持股情况表 1.3公司全体董事出席董事会会议。 1.4本半年度报告未经审计。 单位: 股 ■ 注：2025年7月18日，济川控股解除质押股份65,200,000股，本次解除质押后，剩余质押股份数量为 43,000,000股 2.4截至报告期末的优先股股东总数、前10名优先股股东情况表 □适用 √不适用 2.5控股股东或实际控制人变更情况 √适用 □不适用 ■ 2.6在半年度报告批准报出日存续的债券情况 ...

每经AI快讯，济川药业（SH 600566，收盘价：27.52元）8月23日发布公告称，公司第十届第十六次董 事会会议于2025年8月22日在湖北济川药业股份有限公司办公大楼十楼会议室以现场及通讯表决的方式 召开。会议审议了《关于公司2025年半年度报告全文及摘要的议案》等文件。 每经头条（nbdtoutiao）——汽车涂料龙头"命悬一线"，资金流向成迷，掌控者深藏不露 （记者 张喜威） 2024年1至12月份，济川药业的营业收入构成为：清热解毒类占比33.53%，儿科类占比28.11%，消化类 占比14.41%，其他行业占比9.94%，呼吸类占比8.13%。 ...

（文章来源：证券日报） 证券日报网讯 8月22日晚间，济川药业发布公告称，2025年半年度公司实现营业收入2，748，717， 966.21元，同比下降31.87%；归属于上市公司股东的净利润为724，364，011.18元，同比下降45.87%。 ...

Group 1 - The core viewpoint of the article highlights that Jichuan Pharmaceutical (600566) reported a significant decline in both revenue and net profit for the first half of the year [1] Group 2 - Jichuan Pharmaceutical achieved operating revenue of 2.749 billion yuan, representing a year-on-year decrease of 31.87% [1] - The net profit attributable to shareholders was 724 million yuan, reflecting a year-on-year decline of 45.87% [1] - The company operates in the pharmaceutical manufacturing industry, focusing on the research, production, and sales of drugs [1]

智通财经APP讯，济川药业(600566.SH)发布2025年半年度报告，报告期内，公司实现营业收入27.49亿 元，同比下降31.87%。实现归属于上市公司股东的净利润7.24亿元，同比下降45.87%。实现归属于上市 公司股东的扣除非经常性损益的净利润6.21亿元，同比下降47.43%。基本每股收益0.78元。 ...

Core Viewpoint - Jichuan Pharmaceutical (600566.SH) reported a significant decline in both revenue and net profit for the first half of the year, primarily due to changes in market demand and the impact of medical procurement policies [1] Financial Performance - The company achieved operating revenue of 2,748.718 million yuan, a decrease of 31.87% compared to the same period last year [1] - The net profit attributable to shareholders was 724.364 million yuan, down 45.87% year-on-year [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 620.630 million yuan, reflecting a decline of 47.43% compared to the previous year [1] Market Factors - The decline in revenue and net profit was mainly attributed to reduced sales of Pudilan Anti-inflammatory Oral Liquid and Children's Chiqiao Qingre Granules due to changes in terminal market demand [1] - The sales of Rabeprazole Sodium Enteric-coated Capsules were negatively affected by the medical procurement policy, contributing to the overall revenue and profit decline [1]

格隆汇8月22日丨济川药业(600566.SH)公布，根据公司发展战略规划，公司全资子公司济川药业集团有 限公司于海南设立全资子公司，投资总额10,000万元人民币；拟以海南全资子公司作为投资主体设立香 港全资子公司，投资总额1万元港币。 ...

Core Viewpoint - The report indicates a significant decline in the company's financial performance for the first half of 2025, with a notable drop in revenue and net profit due to changes in market demand and regulatory impacts on key products [1][3][7]. Financial Performance - The company reported a total revenue of CNY 2,748.72 million, a decrease of 31.87% compared to the same period last year [3][16]. - The total profit for the period was CNY 849.04 million, down 45.84% year-on-year [3][16]. - The net profit attributable to shareholders was CNY 724.36 million, reflecting a 45.87% decline from the previous year [3][16]. - Basic earnings per share decreased by 46.21% to CNY 0.78 [3][16]. - The net cash flow from operating activities was CNY 972.47 million, down 37.95% compared to the previous year [3][16]. Business Overview - The company operates in the pharmaceutical manufacturing industry, focusing on the research, production, and sales of drugs, particularly in pediatrics, respiratory, digestive, and gynecological fields [6][8]. - Key products include "Pudilan Anti-inflammatory Oral Liquid" and "Children's Peiqiao Qingre Granules," which have seen a decline in sales due to market demand changes and regulatory impacts [7][8]. Market Position - The company maintains a leading position in its core therapeutic areas, ranking 2nd in the market share for Pudilan Anti-inflammatory Oral Liquid and 1st for Children's Peiqiao Qingre Granules in their respective categories [7][8]. - The company was ranked 33rd in the 2023 China Pharmaceutical Industry Top 100 list and 19th in the 2024 China Pharmaceutical Listed Company Competitiveness Top 20 [6][7]. Product Development and R&D - The company has made progress in its R&D pipeline, with several new drug applications and clinical trials underway [8][12]. - It has submitted 8 Chinese invention patent applications and 1 PCT international patent application during the reporting period [8][12]. Quality Management - The company adheres to strict quality management practices, including compliance with GMP regulations and continuous quality improvement initiatives [9][14]. - It has established a comprehensive auditing system to ensure product quality and compliance across all operational areas [9][14]. Marketing and Sales Strategy - The company employs a professional academic promotion model complemented by channel distribution to enhance market penetration [13][14]. - It actively engages in academic activities to promote its products and strengthen its market presence [13][14].

| | | | | | | | | | | 持有有限 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 的 | | 股东性 | | 持股比 | | | | 持股 | | | | | | | | 质押、标记或冻结 | | 股东名称 | | | | | | | | | | | 售条件的 | | | | | | | 质 例(%) | | | | | | | | 数量 | | | | | | | 股份数量 | | | | | | | | | | | | | 股份数量 | | | | | | | | 境内非 | | | | | | | | | | | | | | | | | | 江苏济川控股集团有限公 | | | | | | | | | | | | | | | | | | 国有法 | | | | | 45.22 | | | 416,757,360 | | | | 0 | 质押 | | | 108,200,000 | | 司 | | ...